microbiologically evaluable

Related by string. * : microbiologically safe . microbiologically / Evaluable : evaluable patients . clinically evaluable patients . clinically evaluable population . patients evaluable . evaluable subjects . clinically evaluable CE . evaluable . efficacy evaluable . clinically evaluable * *

Related by context. Frequent words. (Click for all words.) 67 % CI #.#-#.# [007] 67 % CI #.#-#.# [003] 66 prospectively defined 65 histologically confirmed 64 candidemia 64 Secondary endpoints include 63 recurrent glioblastoma multiforme 63 HBsAg 63 Secondary endpoints included 63 XIENCE V demonstrated 63 pegylated interferon alpha 62 imipenem 62 confidence interval #.#-#.# 62 microbiologic 62 S aureus 62 TAXUS Express Stent 62 paroxysmal AF 61 voriconazole 61 lipid lowering agents 61 heavily pretreated 61 Baseline characteristics 61 Response Evaluation Criteria 61 sustained virological response 61 receiving VELCADE 61 serologic 61 advanced adenomas 61 RECIST criteria 61 active comparator 61 mechanically ventilated patients 60 patients undergoing CABG 60 S. aureus infections 60 HIV uninfected 60 TAXUS p value 60 poor metabolizers 60 seronegative 60 CIMZIA TM 60 seroprotection 60 #mg/day [001] 60 nosocomial infection 60 noninferior 60 mRCC 60 CI #.#-#.# [002] 60 Solid Tumors RECIST 60 LTBI 60 ARCOXIA 60 vismodegib 60 peginterferon 60 chronic HCV infection 60 malignant neoplasms 60 gynecologic procedures 60 irbesartan 60 APTIVUS r 60 peginterferon alfa 2a 60 refractory chronic lymphocytic 60 erythrocyte sedimentation rate 60 J. Clin 59 bacteraemia 59 μmol L 59 infective endocarditis 59 tapentadol ER 59 mcg mL 59 ULORIC 59 TEAEs 59 hypophosphatemia 59 NHANES III 59 lopinavir r arm 59 % CI #.#-#.# [006] 59 mg kg dose 59 μg L 59 tigecycline 59 PREZISTA r 59 T#I [002] 59 chlorambucil 59 ethambutol 59 Moxifloxacin 59 peginterferon alfa 2b 59 NATRECOR R 59 serum phosphorus 59 patients undergoing percutaneous 59 immune modulating 59 mCRC patients 59 plus ribavirin 59 unresectable locally advanced 59 pharmacokinetic parameters 59 C. difficile infections 59 paclitaxel eluting stents 59 vaccinees 59 HCV genotype 1 59 corticosteroid therapy 58 superficial bladder cancer 58 leukopenia 58 lanthanum carbonate 58 breast carcinoma 58 Allovectin 7 ® 58 prespecified 58 achieved PASI 58 R sorafenib tablets 58 ischemic cardiomyopathy 58 diagnosed GBM 58 plus methotrexate 58 CI -#.#

Back to home page